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Different subsets of asthma patients may be recognized according to the exposure trigger and the frequency and severity of clinical
signs and symptoms. Regarding the exposure trigger, generally asthma can be classified as allergic (or atopic) and nonallergic (or
nonatopic). Allergic and nonallergic asthma are distinguished by the presence or absence of clinical allergic reaction and in vitro
IgE response to specific aeroallergens.Themechanisms of allergic asthma have been extensively studied with major advances in the
last two decades. Nonallergic asthma is characterized by its apparent independence from allergen exposure and sensitization and
a higher degree of severity, but little is known regarding the underlying mechanisms. Clinically, allergic and nonallergic asthma
are virtually indistinguishable in exacerbations, although exacerbation following allergen exposure is typical of allergic asthma.
Although they both show several distinct clinical phenotypes and different biomarkers, there are no ideal biomarkers to stratify
asthma phenotypes and guide therapy in clinical practice. Nevertheless, some biomarkers may be helpful to select subsets of atopic
patients whichmight benefit from biologic agents, such as omalizumab. Patients with severe asthma, uncontrolled besides optimal
treatment, notwithstanding nonatopic, may also benefit from omalizumab therapy, although currently there are no randomized
double-blind placebo controlled clinical trials to support this suggestion. However, omalizumab discontinuation according to each
patient’s response to therapy and pharmacoeconomical analysis are questions that remain to be answered.
1. Introduction
Asthma is a heterogeneous disease, usually characterized by
chronic airway inflammation. It is defined by the history of
respiratory symptoms such as wheeze, shortness of breath,
chest tightness, and cough that vary over time and in inten-
sity, together with variable expiratory airflow limitation [1].
The prevalence of asthma, one of the most common
chronic diseases in the world [2, 3], has increased during
the 1970s and 1980s. Epidemiologic studies from the 90s
suggested that the prevalence of asthma was around 7.7% in
the United States (US)—over 22 million people—and lethal-
ity rate was estimated at 5.2 per 100,000 asthmatic patients
per year. Worldwide, 200–300 million people suffer from
asthma [1–3], and severe asthma comprises 5-10% of all
asthmatic patients [4]. In Portugal, the prevalence of asthma
is estimated to be of 6.8% [5], affecting around 1 million
people. Of these, only 57% have controlled disease, which
means that around 300,000 Portuguese asthmatics need a
better intervention to control their disease.
The number of hospitalizations due to asthma was 2,728
in 2016, from a total of 262,229 asthmatic patients registered
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in the Portuguese National Health Service. The standardized
mortality rate was, in 2015, of 4.0/100,000 inhabitants for
patients above 65 years of age, and of 0.1/100,000 inhabitants
for patients below 65 years of age. Nevertheless, and accord-
ing to the latest Organisation for Economic Co-operation
and Development (OECD) report, Portugal is among the
countries with less mortality and the country with less
hospitalizations due to asthma [6].
The high prevalence of asthma, the impairment of quality
of life, the absenteeism, and the large health resources needed
tomanage this disease makes the economic burden of asthma
one of the highest among all chronic diseases. Asthma-related
costs have been estimated at up to 2% of the economic cost of
all diseases in developed countries [7]. A recent systematic
review examined 68 papers on the economic burden of
asthma between 1966 and 2008 and concluded that despite
the availability of effective preventive therapies, the cost of
asthma treatment has increased significantly over the last few
decades [8]. A study conducted in Portugal in 2010 concluded
that asthma in adults poses a significant economic burden
on the Portuguese healthcare system. Total costs amounted
to a grand total of €386,197,211.25, with direct costs repre-
senting 93% or €359,093,559.82, 2.04% of the total Portuguese
healthcare expense in 2010. The major costs were acute care
usage (30.7%) and treatment (37.4%). A considerable portion
of this burdenmight be eased by improving asthma control in
patients, as uncontrolled patients’ costs are more than double
those of controlled asthma patients [9].
Severe asthma has a heterogeneous definition. TheWorld
Health Organization (WHO) suggests that severe asthma
includes three groups: (1) untreated asthma; (2) incorrectly
treated asthma (as a result of nonadherence, persistent trig-
gers, or comorbidities); and (3) difficult-to-treat asthma.
It is also important to distinguish between severe asthma,
comprising patients requiring medium/high doses of inhaled
corticosteroids in combination with LABA or other con-
troller, and uncontrolled asthma, resulting from inappro-
priate therapy or persistent problems with adherence or
comorbidities [1]. According to the British Guidelines for
Asthma, difficult asthma is defined as that with persistent
symptoms and/or frequent asthma attacks despite treatment
with high-dose therapies or continuous or frequent use of oral
steroids [10]. Untreated patients have been recently omitted
in the 2014 revision document produced by the task force of
the European Respiratory Society (ERS) and the American
Thoracic Society (ATS) [11].
Regarding the exposure trigger, generally asthma can be
classified as allergic (or atopic) and nonallergic (or nonatopic
or intrinsic) asthma. Allergic and nonallergic asthma are
distinguished by the presence or absence of clinical allergic
reaction and in vitro IgE response to specific aeroallergens
[12, 13]. The triggering of an inflammatory cascade mediated
by Immunoglobulin E (IgE) mast cells’ activation, with
eosinophils andTh2 lymphocyte synthesis, mobilization, and
activation in the airways with IL-4, IL-5, and IL-13 produc-
tion, leads to bronchial constriction and mucus production
with airways narrowing [14–21]. The mechanisms of allergic
asthma have been extensively studied with major advances
happening in the last two decades. Nonallergic asthma is
characterized by its apparent independence from allergen
exposure and sensitization, but also by a higher degree of
severity [12, 13].
Of note, it is important to distinguish nonallergic asthma
from aspirin exacerbated respiratory disease (AERD) which
also has its own epidemiology, physiopathology, and clinical
features: these patients often develop asthma symptoms years
after developing rhinitis and nasal polyps due to increased
production of cysteinyl–leukotrienes most probably as a
result of a polymorphism of the cysteinyl–leukotriene syn-
thase gene [22].
Whether these different clinical subsets of asthma are due
to different etiopathogenesis or a different spectrum (or phe-
notype) of the same disease resulting from different under-
lying unrecognized mechanisms is still a matter of ongoing
debate [15, 23].
This review was prepared and discussed by a group of
specialists belonging to the Portuguese Network of Severe
Asthma Specialists—REAG.
1.1. Allergic versus Nonallergic Asthma. There are similar
clinical and physiopathological phenomena between allergic
and nonallergic asthma: both can be triggered by exercise,
inhaled irritants, or upper airway tract infection; both are
associated with rhinitis and both can have higher total
serum IgE, airways IgE, airways Th2 cells and Th2, and
eosinophilic chemokines and cytokines. Recently, different
studies have tried to find a common pathophysiological and
immunobiological pattern between both forms of asthma.
According to these studies, nonallergic patients may produce
the same inflammatory mediators as allergic patients after
local IgE production by T lymphocytes at the bronchial and
lung mucosal surface where antigens are presented. This
was demonstrated comparing bronchial biopsies samples
of nonatopic asthma patients, atopic asthma patients, and
nonasthmatic controls [12, 24–27].
Clinically, allergic and nonallergic asthma are virtually
indistinguishable during exacerbations, since both lead to
signs and symptoms of variable lower airways narrowing
and obstruction, which is reversible, at least partially, with
bronchodilators [14, 18, 20, 21, 28].
By definition, allergic asthma is clearly associated with
allergenic triggering, positive skin prick test, and raised
specific IgE (sIgE) [15, 23, 29]. On the other hand, nonallergic
asthma is usually of late onset, shows no familial patterns and
no genetic trends have been recognized [15, 23, 30], has a
higher female prevalence, and tends to be of difficult control
and with more severe relapses. A patient with asthma is
diagnosed with nonallergic asthma if skin prick tests are
negative and no circulating sIgE are found [14, 18, 20, 21, 28,
31, 32].
The relationship between allergic and nonallergic asthma
prevalence is difficult to ascertain. In some studies, non-
allergic asthma prevalence appears to be increasing more
than allergic asthma [15]. According to the Swiss Sentinel
Surveillance Network (SSSN), the consultations for asthma
have decreased over time mainly due to a decrease of allergic
asthma. Consultations for nonallergic asthma did not change
significantly between 1999 and 2005 [33].
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Table 1: Severe asthma phenotypes proposed by Campo et al. [42].
Clinical phenotypes Characteristics
Asthma with frequent severe
exacerbations
Frequent severe exacerbations with periods of relative stability
between exacerbations
Asthma with fixed airflow obstruction Irreversible persistent and progressive airflow obstruction
Corticosteroid-dependent asthma
Symptoms cannot be controlled, despite high doses of ICS, and
patients require daily doses of OCS. Reducing the dose of OCS can
often lead to clinical worsening and exacerbations
Inflammatory phenotypes
Persistent severe eosinophilic asthma
Eosinophilia in bronchial biopsies and induced sputum despite high
doses of ICS or OCS. Characterized by more symptoms, lower FEV
1
values, and more severe exacerbations than the non-eosinophilic
subtype
Non-eosinophilic severe asthma with
increased neutrophils
Eosinophils are either absent from the airway or suppressed by
treatment despite the presence of several symptoms, with
inflammation of the airway characterized by an increased percentage
of neutrophils
Severe paucigranulocytic asthma
It does not involve inflammation by the classical cell types in the
bronchial biopsy. Inflammation may be located in the distal airway,
which is inaccessible for biopsy, or it may be due to a
bronchiolitis-type disease. No thickening of the subepithelial
basement membrane or signs of classic inflammation are observed.
Other inflammation pathways and other cell types could also be
activated
ICS: inhaled corticosteroids; OCS: oral corticosteroids.
The true prevalence of severe asthma among nonallergic
patients compared to allergic asthma patients is uncertain.
Most of the studies assume that severe disease is more preva-
lent among nonatopic asthma patients. There are conflicting
data regarding prevalence trends of asthma and atopy over
the last 10–15 years [33]. The proportion of asthmatics with
severe disease and a negative skin prick test varies from 17 to
34% in the Severe Asthma Research Program (SARP) study
[34] to 50% in the ENFUMOSA study [35]. In the ENFU-
MOSA study, a cross-sectional analysis, it was found that
patients with severe asthma were less likely to be skin prick-
positive and more likely to have high levels of neutrophils in
sputum than patients with less severe asthma [35]. On the
other hand, the U-BIOPRED cohort [36] reported a 76.6%
incidence of atopy in severe asthma, including nonsmokers,
smokers, and ex-smokers.
Although the prevalence and social and financial burdens
of nonallergic asthma seem to be lower than in allergic
asthma [19], from a clinical point of view, nonallergic asthma
is a true challenge: these patients are usually the most difficult
to diagnose, due to their specific epidemiologic features, and
the most difficult to treat and control.
1.2. Phenotypes. There is a complex network of different
mechanistic and clinical features which are likely linked by a
common pattern of reversible respiratory distress associated
to distal airways narrowing. In the last decades efforts
have focused on the classification of different subsets of
asthma patients according to its epidemiology, immunology,
biomarkers, response to specific pharmacotherapies, and
long-term prognosis. These are broadly called phenotypes:
a set of clinical features of a specific genetic pattern in
a specific environment. The main goal of the phenotype
and endotype philosophy is the development of targeted
and personalized pharmacological approaches. Phenotype
definition is particularly important in patients with moderate
to severe disease and who are not controlled with usual
therapy. A detailed and systematic clinical history, including
comorbidities, spirometry with bronchodilator test, a skin or
blood test panel for sIgE to common regional airborne aller-
gens, and a peripheral blood eosinophil count are very useful
for establishing phenotypes. With this information, allergic
and nonallergic asthma and eosinophilic or noneosinophilic
asthma can be distinguished. This distinction has prognostic
and therapeutic implications.
However, although the above-mentioned four pheno-
types are considered to be themajor ones, research on asthma
phenotypes has increased exponentially in the last years and
cluster analysis has identified several distinct clinical pheno-
types of asthma [34, 37–39]. There is, nonetheless, a clear
heterogeneity regarding asthma phenotypes. GINA considers
five phenotypes [1] and Wenzel et al. proposed thirteen
in 2006 [40]. However, in 2012, these thirteen phenotypes
have been reduced to five, due to the evolution towards
linking biology to phenotype, namely, at the molecular and
genetic levels [41]. In 2013, Campo et al. [42] proposed 6
severe asthma phenotypes subdivided in clinical and inflam-
matory phenotypes—Table 1. Smoking is not a phenotype
but a disease modifying factor with prognostic implications
[42].
1.3. Biomarkers. Several biomarkers have been tested for
diagnosis and prediction of clinical response to therapy in
asthma, with the aim of achieving personalized therapy.
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Severe asthma is usually characterized by a type 2 disease,
associated with atopy and/or eosinophilic inflammation of
the airways [43]. However, inflammation in severe asthma is
not always characterized by the presence of eosinophils and
cytokines of the high-Th2 endotype; in many cases, it may
be low-Th2 neutrophilic or low-Th2 paucigranulocytic (type
1 disease) [42].
Currently there are several biomarkers for severe high-
Th2 asthma, but there is a clear need to identify and select
biomarkers of the low-Th2 endotypes. However, this is not
an easy task, and several studies in severe asthmatics, such as
the ENFUMOSA [35], TENOR [44], SARP [34], and, more
recently, the U-BIOPRED [36], have shown a remarkable het-
erogeneity in the clinical presentation and in the underlying
pathophysiological mechanisms of severe asthma.
1.3.1. High-Th2Endotypes. Although heterogeneous, the clas-
sification of the high-Th2 endotypes is mainly based on
sputum and systemic eosinophilia [45], and this is considered
to be a relevant biomarker.These endotypes also show higher
epithelial expression of total IgE [15, 44] and Th2 cytokines
such as interleukines IL-4, IL-5, and IL-13 [15], two of
which, IL-4 and IL13, directly contribute to IgE class switch,
thereby increasing IgE [46]. Other known and established
biomarkers of Th2 predominant asthma are exaled nitric
oxide (FeNO) [47–50] and serum periostin [51]. In a recent
study by Busse et al. [52], the authors defined high-Th2 as IgE
≥100 IU/ml, eosinophils count ≥ 300/𝜇l, and FeNO ≥30 ppb.
Currently, total IgE and serum eosinophils are used not only
as disease biomarkers but also as variables on the treatment
algorithm of a specific subgroup of severe asthmatic patients
who are eligible for anti-IgE omalizumab [53] or anti-IL5
mepolizumab [54]. Indeed, an analysis of biomarkers of the
EXTRA study [55] showed that combining biomarkers on the
high-Th2 endotypes had therapeutic response implications:
patients with severe atopic asthma with high IgE values and
Th2 biomarkers (high blood eosinophils and periostin and
high FeNO values) showed a better response to omalizumab
therapy.
1.3.2. Low-Th2 Endotypes. Although high-Th2 asthma with
atopy and eosinophilia is easy to identify, there is no accepted
and consensual definition for the low-Th2 endotypes [56–
58], which comprise around one-third of severe asthmatic
patients [59].
Low-Th2 endotypes are currently identified in clinical
practice as the absence of biomarkers of atopic asthma and/or
eosinophilia. In the majority of cases, the low-Th2 endotypes
are defined by the absence of Th2 inflammatory biomarkers
and characterized as neutrophilic inflammation and, less
frequently, by paucigranulocytic inflammation [42, 56].
Although there is no consensus regarding the percentage
of sputum neutrophils that would define the neutrophilic
asthma phenotype, some reports mention values between 40
and 70% [59].
Beyond the sputum leukocyte content, other specific
biomarkers that are able to discriminate high-Th2 from
low-Th2 are currently under investigation, but are still not
applicable in clinical practice.
IL-8 is a cytokine associated with chemotaxis and neu-
trophilic degranulation and has been found to be elevated in
the sputum of patients with severe resistant asthma [60–62].
CXCR1 and CXCR2 have been also found to be elevated in
neutrophilic asthma [62]. Other potential biomarkers of neu-
trophilic asthma are myeloperoxidase [62] and neutrophilic
elastase [61, 62] that can be assessed in sputum of this
subgroup of severe asthmatics.
IL-17 is a biomarker of activation of theTh17 pathway, and
correlations between the presence of IL-17 and the level of
neutrophils in induced sputum and in circulation have been
found in patients with severe asthma [62, 63].
There are currently no biomarkers for the subgroup of
patients with paucigranulocytic asthma [62]. In this popula-
tion of patients there is no predominant inflammatory type,
and it is possible that other biomarkers of severe asthma,
namely, biomarkers of airway remodelling such as osteopon-
tin and angiopoietin, are relevant.
It is necessary to unravel the pathophysiological mech-
anisms of low-Th2 endotypes in order to identify future
biomarkers of these subtypes of asthma [41, 56, 62].
Currently there are no accurate or precise biomarkers
to stratify asthma phenotypes and guide therapy in clinical
practice, as illustrated in Figure 1.
1.4. Effect of Interaction of Comorbidities. Uncontrolled aller-
gic rhinitis, gastroesophageal reflux disease (GERD), obesity,
vitamin D deficiency, noncompliance to therapy, and trigger
exposure are among the most important effect modifiers of
asthma. Of these, due to its prevalence, obesity is one of the
most feared comorbidities in asthma patients.
Obese asthma patients show synergy among the two
pathologies, i.e., the complexity of the disease is higher than
the sum of the diseases, and this interaction worsens the
prognosis. Obesity worsens preexisting asthma, through both
biochemical and mechanical effects, and potentially impairs
response to treatment, and obese patients are more likely
to suffer from nonallergic asthma than nonobese patients
[64, 65].
Even in obese asthmatic patients it seems to be possible
to distinguish two different clinical courses based on age
of onset and Th2 related biomarkers: early-onset asthma
tends to have a more atopic disease, higher IgE, and greater
bronchial hyperresponsiveness. These patients seem to have
allergic asthma that is complicated by obesity. On the other
hand, obese patients with late-onset asthma tend to have less
atopy, bronchial hyperresponsiveness, and lower levels ofTh2
inflammation. These patients have asthma that has developed
in the setting of obesity [66].
2. Treatment Options for Severe Allergic and
Nonallergic Asthma
The aim of therapy in asthma is achieving disease control.
Disease control is considered by the British Thoracic Society
[10] as
(i) no daytime symptoms
(ii) no night-time awakening due to asthma
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Figure 1: Proposed biomarkers to stratify asthma by phenotypes are still not robust enough to guide therapy in clinical practice.
(iii) no need for rescue medication
(iv) no asthma attacks
(v) no limitations on activity including exercise
(vi) normal lung function (in practical terms FEV1 and/or
PEF>80% predicted or best)
(vii) minimal side effects from medication.
The clinical management of nonallergic asthma is similar to
that of allergic asthma. It comprises a combination of non-
pharmacological approaches, namely, trigger avoidance and
control of comorbidities and pharmacological approaches
[1, 10, 67]. Pharmacological approach initiates with ICS as
the mainstay of therapy with the addition of LABA if this is
insufficient to control symptoms [1, 10, 67]. Additional add-
on therapy to ICS and LABA according to disease control
includes increasing doses of ICS or add-on LAMA, LTRA,
or theophylline [1, 10]. Almost 90% of asthma patients can
generally be controlled with ICS and LABA.Of the remaining
10%, between 17% and 50% are nonallergic asthma according
to the SARP and ENFUMOSA studies [34, 35]. The U-
BIOPRED study reported a 30% incidence of nonatopy in the
asthma groups [36].
The presence of comorbidities should prompt the initia-
tion of nonpharmacological and pharmacological strategies
towards comorbidities, namely, obesity and GERD.
With the breakthrough of monoclonal antibodies (mAbs)
therapies on the verge of the 21st century new pharma-
cological approaches have been developed and tested in
these patients [24, 68]. Therapy with mAbs is a specific
subset of immunotherapy using passive immunity in which
preformed antibodies against a target antigen are injected
into the body. MAbs can efficiently target an antigen blocking
or initiating a biochemical cascade event and through this
mechanism achieve a clinical response [24, 68]. This implies
a much higher linkage between pathophysiology, clinical
and pharmacotherapy to select the subset of patients who
will benefit the most from biological therapy, which revisits
phenotypes, immunobiology and endotypes.
2.1. Treatment Options in Severe Allergic Asthma. Sputum
analysis and FeNO are very useful in predicting Th2 asthma
phenotype, even if no eosinophilia is present. This is of
utmost importance to therapeutic strategy definition: allergic
asthma with elevated eosinophils and FeNO is more likely
to respond to ICS [16] and omalizumab [55]. Allergic Th2
phenotype poorly controlled asthmatic patients should be
considered good candidates for omalizumab therapy after
add-on ICS/LABA/leukotriene/theophylline therapy [69–
71].
Omalizumab is a monoclonal antibody designed to bind
and inactivate IgE and was approved by EMA in 2009. For
patients ≥6 years old omalizumab is indicated as add-on
therapy to improve asthma control in patients with severe
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persistent allergic asthma who have a positive skin test or in
vitro reactivity to a perennial aeroallergen and frequent day-
time symptoms or night-time awakenings and who have had
multiple documented severe asthma exacerbations despite
daily high-dose inhaled corticosteroids, plus a long-acting
inhaled beta2-agonist. For patients ≥12 years of age a reduced
lung function (FEV
1
<80%) is also required [72].
Omalizumab blocks free serum IgE and limits its binding
to the Fc𝜀RI receptor on the surface of mast cells and
basophils. This blockade leads to a reduction in the specific
inflammatory response induced by activation of effector cells
during the encounter with the allergen [73].
Omalizumab has been also demonstrated to reduce the
expression of Fc𝜀RI on the surface of circulating mast cells
and basophils [74, 75] which results in a decrease in the
release of mediators induced by allergenic stimuli in vitro and
in vivo [74, 76, 77]. Omalizumab also seems to intervene in
the regulation of the number of circulating basophils which
decreases in the treated child [78].
Beyond the anti-IgE mechanism centered on basophils
and mast cells, several recent experimental data and clinical
observations show that the mechanism of action of oma-
lizumab is more complex than just blocking the allergic
response, some of which are mentioned below.
Several studies have shown a decrease in the number of
circulating eosinophils and bronchial tissue eosinophils in
asthmatics treated with omalizumab [79–82]. Patients with
steroid-resistant asthma have been shown to have higher
levels of eosinophils, and in these cases omalizumab is a very
effective treatment, reducing circulating eosinophils [83].
A proapoptotic effect of omalizumab on eosinophils may
contribute to this decrease [84]. Moreover, a study exploring
the potential of three biomarkers ofTh2-driven inflammation
(FeNO, peripheral blood eosinophils, and serumperiostin) to
predict response to treatment to omalizumab in patients with
severe allergic asthma concluded that patients in the high-
biomarker subgroup showed a significant decrease in the
percentage of exacerbations compared to the low-biomarker
subgroup, suggesting that these patients may achieve greater
benefit from omalizumab therapy. However, the benefit
of such a predictive biomarker of efficacy of omalizumab
therapy is currently not established [55].
In a recent study of 673 patients, high levels of periostin
and NO exhaled before treatment with omalizumab were
associated with a significant decrease in the number of exac-
erbations [55]. Omalizumab appears to be targeting this Th2
inflammation and a decrease in exhaled NO after treatment
has been found in various studies [85]. High levels of
these markers prior to initiation of omalizumab have been
proposed as biomarkers that predict efficacy with this therapy
[55].
Various in vitro, ex vivo, and/or in vivo studies from
blood samples, bronchial biopsies, or exhaled air condensates
have shown mainly a decrease in the cytokines involved in
the recruitment, activation, and survival of eosinophils and
IL-5, IL-13, IL-4, IL-8, GM-CSF, eotaxin, RANTES, and the
Th2 orientation of the immune response. IFN-𝛾, an anti-
inflammatory cytokine, was not modified in two ex vivo
studies after 16 weeks of treatment with omalizumab [81, 86].
A modulation of the transcription and/or secretion of these
different cytokines could thus contribute to a decrease in the
recruitment and activation of the inflammatory cells involved
in the late inflammatory stage of asthma and reduce long-
term remodelling of the airways [87].
In addition to the above, omalizumab has a preventive
effect on viral-induced exacerbations in children with aller-
gic asthma, since blocking IgE decreases susceptibility to
rhinovirus infections and illness [88]. Dendritic cells play a
crucial role in innate immune defence against infections, par-
ticularly viral infections [89]. During the respiratory allergic
response, dendritic cells ensure the presentation of antigens
to T lymphocytes and are also capable of polarizing näıve T
lymphocytes inTh2 lymphocytes [90].Dendritic cells express
the Fc𝜀RI receptor on their surface, such as basophils and
mast cells [91]. The binding of IgE to dendritic cells inhibits
their antiviral capacities [92, 93]. A decrease in the expression
of Fc𝜀RI on dendritic cells induced by omalizumab may
enhance antiviral immune responses and participate in the
prevention of a significant number of asthma exacerbations
as demonstrated [88].
2.2. Treatment Options in Severe Nonallergic Asthma. Pa-
tients with nonallergic asthma are usually more severe and
require higher doses of ICS to control symptoms, which may
reflect the fact that there may be a degree of corticosteroid
resistance as a result of superantigen exposure and activation
of MAP kinase pathways [15, 24]. Although patients with
severe asthma represent “only” 10% of asthmatic patients,
they are the most challenging and with most impairment of
quality of life and absenteeism [1, 8, 19].
Severe asthma patients with a non-Th2 phenotype with
sputum neutrophilia might benefit from macrolide therapy
[16]. A very recent study showed that azithromycin reduced
asthma exacerbations in both severe eosinophilic and
noneosinophilic asthma, suggesting an immunomodulatory
effect ofmacrolides [94].This immunomodulatory effectmay
be a possible mechanism of action of omalizumab in both
eosinophilic and noneosinophilic asthma. On the other hand,
patients with nonallergic but with clear high-Th2 features
might be considered good candidates for biotherapies against
IL-5, such as mepolizumab or reslizumab [69–71].
In nonallergic asthma, there is frequent elevation of total
IgE, including at the bronchial tissue level [95] and it is now
established that dendritic cells participate in its pathophys-
iology [96, 97]. As in allergic asthma, omalizumab reduces
the expression of Fc𝜀RI on the dendritic cells of nonallergic
asthma patients [12]. It is likely that other cells expressing
Fc𝜀RI involved in the pathophysiology of certain nonaller-
gic asthma phenotypes are targeted by omalizumab [98].
Evidence and especially good quality evidence is emerging
regarding the efficacy and safety of off-label uses of omal-
izumab in severe nonallergic asthma [12, 24, 53, 68, 99–106].
The field of action of omalizumab is therefore not limited
to a simple anti-IgE activity. The molecule can inflect airway
remodelling on one hand and induce clinical efficacy in non-
allergic pathologies, but the mechanisms of action at the cel-
lular and cytokine level, anti-Th2 and anti-inflammation, still
need to be clarified. In-depth knowledge of the mechanisms
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of action of omalizumab would make it possible to identify
predictive biomarkers of efficacy, which are valuable in the
phenotyping and therapeutic management of patients with
severe asthma.
3. Conclusions
Although no good quality evidence is currently available
to determine which patients with severe nonatopic asthma
should be selected for omalizumab treatment, some issues
should always be kept in mind: (a) the diagnosis of nonatopic
asthma is not easy and should be carefully confirmed; (b)
the definition of severe asthma is heterogeneous and should
always be carefully assessed; (c) biomarkers may be helpful
to select subsets of patients which might benefit from oma-
lizumab treatment; (d) poor adherence and comorbidities,
mainly obesity, interact negatively with asthma and should
always be addressed with specific pharmacological and non-
pharmacological measures. Based on literature and clinical
experience of the authors, there is a clear benefit for allergic
asthma patients to be treated with omalizumab. Moreover,
those patients with severe nonatopic asthma (including those
with high FeNO as a marker of IL-13 inflammation, high
eosinophils, and periostin), uncontrolled besides optimal
nonpharmacological and pharmacological treatment, may
benefit from omalizumab therapy. However, when to sus-
pend omalizumab according to response to therapy in each
patient and pharmacoeconomical analysis are questions that
remain to be answered.
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and J. A. Fonseca, “Cost of asthma in Portuguese adults: A
population-based, cost-of-illness study,” Revista Portuguesa de
Pneumologia (English Edition), vol. 23, no. 6, pp. 323–330, 2017.
[10] D. R. James and M. D. Lyttle, “British guideline on the man-
agement of asthma: SIGN Clinical Guideline 141, 2014,” ADC -
Education and Practice Edition, vol. 101, no. 6, pp. 319–322, 2016.
[11] K. F. Chung, S. E. Wenzel, J. L. Brozek et al., “International
ERS/ATS guidelines on definition, evaluation and treatment of
severe asthma,” European Respiratory Journal, vol. 43, no. 2, pp.
343–373, 2014.
[12] G. Garcia, A. Magnan, R. Chiron et al., “A proof-of-concept,
randomized, controlled trial of omalizumab in patients with
severe, difficult-to-control, nonatopic asthma,”CHEST, vol. 144,
no. 2, pp. 411–419, 2013.
[13] A. Nieves, A.Magnan, S. Boniface et al., “Phenotypes of asthma
revisited upon the presence of atopy,” Respiratory Medicine, vol.
99, no. 3, pp. 347–354, 2005.
8 BioMed Research International
[14] A. S. Amoah, A. G. Forson, and D. A. Boakye, “A review of
epidemiological studies of asthma in Ghana.,” Ghana Medical
Journal, vol. 46, no. 2, pp. 23–28, 2012.
[15] P. J. Barnes, “Intrinsic asthma: not so different from allergic
asthma but driven by superantigens?” Clinical & Experimental
Allergy, vol. 39, no. 8, pp. 1145–1151, 2009.
[16] J. Corren, “Asthma phenotypes and endotypes: an evolving
paradigm for classification,” Discovery Medicine, vol. 15, no. 83,
pp. 243–249, 2013.
[17] J. Crane, P. Lampshire, K. Wickens et al., “Asthma, atopy and
exhaled nitric oxide in a cohort of 6-yr-old New Zealand
children,” Pediatric Allergy and Immunology, vol. 23, no. 1, pp.
59–64, 2012.
[18] C. Janson, P. Kalm-Stephens, T. Foucard, K. Alving, and S. L.
Nordvall, “Risk factors associatedwith allergic and non-allergic
asthma in adolescents,” The Clinical Respiratory Journal, vol. 1,
no. 1, pp. 16–22, 2007.
[19] M.-H. Lafeuille, J. Gravel,M. Figliomeni, J. Zhang, and P. Lefeb-
vre, “Burden of illness of patients with allergic asthma versus
non-allergic asthma,” Journal of Asthma & Allergy Educators,
vol. 50, no. 8, pp. 900–907, 2013.
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